See more : Associated Alcohols & Breweries Limited (ASALCBR.NS) Income Statement Analysis – Financial Results
Complete financial analysis of NexgenRx Inc. (NEGXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NexgenRx Inc., a leading company in the Medical – Healthcare Plans industry within the Healthcare sector.
You may be interested
- Arsenal Digital Holdings, Inc. (ADHI) Income Statement Analysis – Financial Results
- Archidply Decor Limited (ADL.NS) Income Statement Analysis – Financial Results
- Navient Corporation (0K5R.L) Income Statement Analysis – Financial Results
- KludeIn I Acquisition Corp. (INKAU) Income Statement Analysis – Financial Results
- AIFarm, Ltd. (AIFM) Income Statement Analysis – Financial Results
NexgenRx Inc. (NEGXF)
About NexgenRx Inc.
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers prescription drug claims; dental claims; and claims for the extended health benefits, as well as a health care spending account that provides an amount of money to an individual to pay for health or dental benefits. The company also offers individual and aggregate stop loss products; medical emergency and travel assistance insurance services; administrative services, including the collection and payment of premiums for life and LTD coverage, as well as a suite of reporting tools; Web claims submission services; direct deposit services; and ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.85M | 12.46M | 11.88M | 10.42M | 9.58M | 6.93M | 5.72M | 5.80M | 4.68M |
| Cost of Revenue | 3.03M | 3.97M | 3.39M | 2.32M | 2.06M | 1.44M | 1.27M | 1.19M | 1.05M |
| Gross Profit | 10.82M | 8.49M | 8.49M | 8.10M | 7.52M | 5.49M | 4.46M | 4.60M | 3.63M |
| Gross Profit Ratio | 78.14% | 68.16% | 71.47% | 77.75% | 78.48% | 79.18% | 77.86% | 79.39% | 77.48% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 740.99K | 879.22K | 752.86K | 674.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 533.46K | 825.24K | 274.19K | 334.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.27M | 8.42M | 6.33M | 6.59M | 7.64M | 6.26M | 5.02M | 4.08M | 3.94M |
| Other Expenses | 9.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.82M | 8.42M | 6.33M | 6.59M | 7.64M | 6.26M | 5.02M | 4.08M | 3.94M |
| Cost & Expenses | 13.85M | 12.38M | 9.72M | 8.90M | 9.70M | 7.70M | 6.29M | 5.28M | 5.00M |
| Interest Income | -122.83K | 205.71K | 54.94K | 649.65K | 219.72K | 212.22K | 29.74K | -35.77K | -24.53K |
| Interest Expense | 38.35K | 151.84K | 190.83K | 349.01K | 384.61K | 162.92K | 97.40K | 104.87K | 102.04K |
| Depreciation & Amortization | 1.31M | 1.39M | 1.35M | 939.10K | 855.45K | 316.12K | 131.85K | 75.77K | 74.29K |
| EBITDA | 1.03M | 1.68M | 4.33M | 2.45M | 951.52K | -436.43K | -435.55K | 691.48K | -242.11K |
| EBITDA Ratio | 7.45% | 11.82% | 29.52% | 23.54% | 7.64% | -6.52% | -7.61% | 10.29% | -5.17% |
| Operating Income | -190.71K | 79.41K | 2.16M | 1.51M | -123.65K | -767.97K | -567.40K | 520.72K | -316.39K |
| Operating Income Ratio | -1.38% | 0.64% | 18.20% | 14.53% | -1.29% | -11.07% | -9.91% | 8.98% | -6.76% |
| Total Other Income/Expenses | -114.35K | -253.23K | -777.76K | -941.70K | -413.12K | 40.37K | 38.60K | -104.87K | 128.55K |
| Income Before Tax | -305.06K | 133.28K | 2.03M | 1.81M | -288.54K | -718.68K | -635.06K | 415.85K | -187.84K |
| Income Before Tax Ratio | -2.20% | 1.07% | 17.05% | 17.42% | -3.01% | -10.36% | -11.09% | 7.17% | -4.01% |
| Income Tax Expense | 26.92K | 155.49K | -2.02M | -306.46K | -74.94K | -24.02K | 3.81 | -176.29K | 2.77 |
| Net Income | -331.97K | -22.20K | 4.05M | 2.12M | -213.60K | -694.65K | -635.06K | 592.14K | -187.84K |
| Net Income Ratio | -2.40% | -0.18% | 34.09% | 20.36% | -2.23% | -10.02% | -11.09% | 10.21% | -4.01% |
| EPS | 0.00 | 0.00 | 0.06 | 0.03 | 0.00 | -0.01 | -0.01 | 0.01 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.05 | 0.03 | 0.00 | -0.01 | -0.01 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 70.54M | 70.34M | 70.34M | 69.92M | 69.92M | 68.23M | 60.30M | 58.78M | 57.19M |
| Weighted Avg Shares Out (Dil) | 70.53M | 70.34M | 74.84M | 69.92M | 69.92M | 68.23M | 60.30M | 59.63M | 57.19M |
NexgenRx Announces Third Quarter Results and Declaration of Divdend
TORONTO, ON / ACCESSWIRE / November 25, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2024, with quarterly revenue increasing to $4,158,667 in Q3 2024 and...
NexgenRX Announces Director Re-Appointment
TORONTO, ON / ACCESSWIRE / October 7, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the re-appointment of Charles Burns to its Board of Directors effective immediately.
NexgenRx Announces New Director
TORONTO, ON / ACCESSWIRE / October 1, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the appointment of Linda Brennan to its Board of Directors effective immediately.
NexgenRx Announces Second Quarter Results, With Over 19% Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESSWIRE / August 15, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the second quarter ended June 30, 2024, with quarterly revenue increasing to $4,084,839, and increased positive EBITDA...
NexgenRx Announces Share Issuances Under Consulting Agreement
TORONTO, ON / ACCESSWIRE / July 18, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the issuance of an aggregate of 195,312 common shares at a price of $0.32 in respect of the fourth quarterly equity...
NexgenRx Announces Declaration of Dividend
NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred...
NexgenRx Announces First Quarter Results, with 24% Revenue Growth and Record Earnings
TORONTO, ON / ACCESSWIRE / May 17, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the first quarter ended March 31, 2024, with revenue of $4,292,731, Net Income of $460,949 and EBITDA...
NexgenRx Announces Annual Meeting Results
TORONTO, ON / ACCESSWIRE / May 16, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the results of its annual and special meeting (the "Meeting") of shareholders, which was held on Thursday, May 16, 2024.
NexgenRx Announces 2023 Year End Results With Solid Revenue Growth, Continuing Positive EBITDA
TORONTO, ON / ACCESSWIRE / April 5, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2023, with continued revenue growth to $3,573,751 for the quarter...
NexgenRx Announces Director Resignation
TORONTO, ON / ACCESSWIRE / December 29, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") announces the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such...
Source: https://incomestatements.info
Category: Stock Reports